ASH 2023 | Intensive induction chemotherapy vs HMA/Ven in NPM1-mutant AML: a retrospective study
Jan Philipp Bewersdorf, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on a multicenter retrospective cohort study, which aimed to compare intensive induction chemotherapy (cytarabine plus anthracycline) to venetoclax (Ven) plus hypomethylating agent (HMA) therapy regimens in patients with newly diagnosed NPM1-mutant acute myeloid leukemia (AML). As comparable disease outcomes were observed in the two treatment regimens, further investigation, through the use of randomized clinical trials, is necessary to allow conclusions to be drawn about which treatment should be preferentially administered in this patient population. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
